Related Experiment Video
Updated: May 17, 2026

Detection of Functional Matrix Metalloproteinases by Zymography
Published on: November 8, 2010
[Preparation, identification and application of monoclonal antibody against matrix metalloproteinases-2]
Mu You1, Wen Liu, Zhen-shan Xu
1Department of Medicine, Huainan Union University, Huainan, China.
Aim:
To prepare and characterize monoclonal antibodies against matrix metalloproteinase-2 (MMP-2), check its expression in the tissues of human ovarian cancer and transplanted tumors in nude mice.
Methods:
MMP-2 were linked to the carrier protein bovine serumalbumin (BSA) and keyhole limpet hemocyanin (KLH) using glutaraldehyde method to obtain MMP-2-BSA and MMP-2-KLH, respectively. The anti-MMP-2 monoclonal antibody was obtained through hybridoma technique. We established the cell strains secreting mAb by hybridoma technique and prepared the mAb by induction of ascites in vivo. The prepared mAb was purified by salting out with ammonium sulfate and identified by ELISA and Western blotting. We compared the mAb and commercial polyclonal antibody by immunohistochemistry and detected the expressions of MMP-2 and CA125 in ovarian cancer issues and transplanted tumor.
Results:
The artificial antigen and 3 hybridoma cell lines secreting monoclonal antibodies (mAb) against MMP-2 were obtained. The subclasses of mAb were all IgG1. The titer of peritoneal exudates was 1:1×10(6);. The expressions of MMP-2 and CA125 in transplanted tumor and ovarian cancer tissues were all high. The positive expression rate of MMP-2 checked using generated antibody was 71.2%(57/80) in ovarian cancer tissues and 16.67% (5/30) in normal tissues, with significant difference between them (P<0.01). In early stage, the positive rate of MMP-2 and CA125 combined detection was higher than that of CA125 detection alone (P<0.01). The mAb was suitable for detecting the expression of MMP-2 in human tissues and gave results consistent with commercial polyclonal antibody. The mAb was more specific than commercial mAb (P<0.01).
Conclusion:
The anti-human MMP-2 mAb is successfully prepared, which may serve as a valuable tool in the functionaI studies of ovarian cancer.
